Edition:
United Kingdom

Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

3.63USD
22 Jul 2019
Change (% chg)

-- (--)
Prev Close
$3.63
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
119,683
52-wk High
$4.61
52-wk Low
$1.75

Latest Key Developments (Source: Significant Developments)

Chimerix Reports Q1 Loss Per Share Of $0.35
Thursday, 9 May 2019 

May 9 (Reuters) - Chimerix Inc ::CHIMERIX ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND STRATEGY UPDATE.Q1 LOSS PER SHARE $0.35.Q1 EARNINGS PER SHARE ESTIMATE $-0.35 -- REFINITIV IBES DATA.Q1 REVENUE $2.4 MILLION VERSUS $800,000.RESTRUCTURING TO REDUCE WORKFORCE BY MORE THAN 50%, MAINTAINING KEY CAPABILITIES AND PRESERVING CAPITAL FOR NEW PROGRAMS.PLAN TO FOCUS ON EXECUTION OF SMALLPOX PROGRAM, HALTING ALL OTHER BRINCIDOFOVIR DEVELOPMENT ACTIVITIES.REPORTS POSITIVE TOP-LINE SURVIVAL DATA FROM PIVOTAL MOUSE STUDY AS KEY MILESTONE ON PATH TO SMALLPOX REGULATORY SUBMISSION.CHIMERIX - DISCONTINUATION ONGOING HUMAN CLINICAL TRIALS FOR ORAL AND INTRAVENOUS BRINCIDOFOVIR DUE TO LOW PATIENT ACCRUAL ACROSS ALL ACTIVE TRIALS..INTENDS TO PURSUE EXTERNAL OPPORTUNITIES TO BUILD ITS PIPELINE OF PRODUCT CANDIDATES.  Full Article

Chimerix Q3 Loss Per Share $0.33
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Chimerix Inc ::CHIMERIX ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.33.Q3 REVENUE $400,000 VERSUS $900,000.Q3 EARNINGS PER SHARE VIEW $-0.42 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE VIEW $974,000 -- THOMSON REUTERS I/B/E/S.  Full Article

Chimerix Receives Orphan Drug Designation From The FDA For Brincidofovir For The Treatment Of Smallpox
Thursday, 7 Jun 2018 

June 7 (Reuters) - Chimerix Inc ::CHIMERIX RECEIVES ORPHAN DRUG DESIGNATION FROM THE FDA FOR BRINCIDOFOVIR FOR THE TREATMENT OF SMALLPOX.CHIMERIX - U.S. FDA GRANTED ORPHAN DRUG DESIGNATION FOR BRINCIDOFOVIR FOR TREATMENT OF SMALLPOX.  Full Article

Chimerix Announces Q4 Loss Per Share $0.41
Thursday, 1 Mar 2018 

March 1 (Reuters) - Chimerix Inc ::CHIMERIX ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.41.Q4 REVENUE $1.8 MILLION VERSUS $2.0 MILLION.  Full Article

Chimerix Inc entered into agreement with Cowen and Co
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Chimerix Inc :On November 8, 2017, co entered into an at market issuance, or ATM, sales agreement with Cowen and Company LLC - SEC filing​.Under agreement co may offer and sell shares of its common stock, $0.001 per share, having aggregate gross proceeds of up to $75 million​.  Full Article

Chimerix reports Q3 loss of $0.37/shr
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Chimerix Inc :Chimerix announces third quarter 2017 financial results.Q3 loss per share $0.37.Q3 revenue $900,000 versus I/B/E/S view $850,000.Q3 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S.  Full Article

Chimerix reports Q2 loss per share $0.36
Monday, 7 Aug 2017 

Aug 7 (Reuters) - Chimerix Inc :Chimerix announces second quarter 2017 financial results.Q2 loss per share $0.36.Q2 revenue $700,000 versus $1.8 million.Q2 revenue view $1.2 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.  Full Article